Gonzalez Victoria, Suflita Michael, Janitz Amanda, Campbell Janis, McIntosh Andrew G, Stratton Kelly, Cookson Michael S, Parker Daniel C
Department of Urology, The University of Oklahoma Health Sciences Center & The Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Department of Biostatistics & Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
J Cancer Epidemiol. 2022 Jun 19;2022:2689386. doi: 10.1155/2022/2689386. eCollection 2022.
This cohort study describes the differences in kidney cancer age-adjusted incidence and mortality rates between American Indians/Alaskan Natives (AI/ANs) and Whites in Oklahoma. Additionally, rates for the U.S. are updated to establish an epidemiological comparison between Oklahoma and the rest of the country.
Kidney cancer age-adjusted incidence and mortality rates for Oklahoma were gathered using the Oklahoma Central Cancer Registry since 1999. National rates were obtained from the Center for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database between 1997 and 2017. Rate ratios were used to compare incidence and mortality rates for AI/ANs and Whites within Oklahoma as well as the entire country. Joinpoint regression models were created to illustrate trends in kidney cancer incidence and mortality.
The age-adjusted incidence rate of kidney cancer in Oklahoma for AI/ANs and Whites was 32.3 and 15.8 per 100,000, respectively, for an incidence rate ratio of 2.04. The national incidence rate ratio was 0.89. The age-adjusted mortality rate in Oklahoma for AI/ANs and Whites was 9.78 and 4.98 per 100,000, respectively, for a mortality rate ratio of 1.98. Oklahomans, irrespective of race, fare worse in terms of kidney cancer mortality compared to the rest of the country.
In Oklahoma, AI/ANs are more likely than Whites to have a kidney cancer diagnosis. AI/ANs are twice as likely to die from kidney cancer than Whites in Oklahoma. AI/AN populations in certain states may benefit from kidney cancer early screening initiatives.
本队列研究描述了俄克拉荷马州美国印第安人/阿拉斯加原住民(AI/ANs)与白人之间肾癌年龄调整发病率和死亡率的差异。此外,更新了美国的发病率和死亡率,以便在俄克拉荷马州与美国其他地区之间进行流行病学比较。
自1999年起,利用俄克拉荷马州中央癌症登记处收集该州肾癌年龄调整发病率和死亡率。1997年至2017年期间的全国发病率和死亡率数据来自疾病控制与预防中心的广泛在线流行病学研究数据库。采用发病率比来比较俄克拉荷马州以及整个美国AI/ANs和白人的发病率和死亡率。建立连接点回归模型以说明肾癌发病率和死亡率的趋势。
俄克拉荷马州AI/ANs和白人的肾癌年龄调整发病率分别为每10万人32.3例和15.8例,发病率比为2.04。全国发病率比为0.89。俄克拉荷马州AI/ANs和白人的肾癌年龄调整死亡率分别为每10万人9.78例和4.98例,死亡率比为1.98。无论种族如何,俄克拉荷马州居民的肾癌死亡率均高于美国其他地区。
在俄克拉荷马州,AI/ANs被诊断出患有肾癌的可能性高于白人。在俄克拉荷马州,AI/ANs死于肾癌的可能性是白人的两倍。某些州的AI/AN人群可能会从肾癌早期筛查计划中受益。